FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034625404> ?p ?o ?g. }

• W2034625404 endingPage "1506" @default.
• W2034625404 startingPage "1498" @default.
• W2034625404 abstract "Abstract BACKGROUND The purpose of the study was to determine, in a Phase I/II study, the efficacy and safety profile of thalidomide with interleukin‐2 (IL‐2) in patients with metastatic renal cell carcinoma (MRCC). METHODS Fifteen patients (8 of whom were previously treated) enrolled in Phase I were treated with escalating doses of oral thalidomide (200–600 mg) and a fixed dose of IL‐2 (7 mIU/m 2 ) by subcutaneous injection. A course was 6 weeks, with the exception of Course 1, which was 7 weeks. Thirty‐seven Phase II patients who had not received prior chemotherapy or immunotherapy for renal cell carcinoma (RCC) received an initial thalidomide dose of 200 mg at Week 0, which was escalated to 400 mg after 48 hours. Subcutaneous IL‐2 was administered at the same fixed daily dose used in Phase I. RESULTS Fifty‐one of 52 Phase I/II patients were evaluable. Twenty‐seven patients (52%) experienced disease control, including 4 (8%) complete responses, 15 (29%) partial responses, and 8 (15%) cases of stable disease. Disease progression was observed in 24 patients (47%). Survival in the 2 phases ranged from 4 weeks to 45.2+ months. At the time of last follow‐up, 2 of 51 patients (4%) remained on maintenance thalidomide therapy and continue to be followed. Three of the 51 patients with CRs (6%) ceased thalidomide therapy at 23–25 months and have maintained their responses to date. One complete responder was lost to follow‐up. As of January 2005, 14 of 51 patients (27%) remained alive. Toxicities were mild to moderate, including Grade 1 to 2 somnolence, constipation, neuropathy, rash, flu‐like symptoms, fluid retention, hypotension, and hypothyroidism (according to version 2.0 of National Cancer Institute Common Toxicity Criteria). In addition, two patients experienced deep venous thrombosis. CONCLUSIONS Thalidomide in combination with IL‐2 is tolerable and can produce durable, active responses in patients with MRCC. To evaluate the merits of thalidomide as a valuable agent against MRCC and to more fully determine the efficacy of thalidomide/IL‐2 combination therapy, the scrutiny of Phase III testing is required. Further development of thalidomide/IL‐2 combination therapy will be the focus of this group. Cancer 2006. © 2006 American Cancer Society." @default.
• W2034625404 created "2016-06-24" @default.
• W2034625404 creator A5014373184 @default.
• W2034625404 creator A5017558949 @default.
• W2034625404 creator A5021341031 @default.
• W2034625404 date "2006-03-16" @default.
• W2034625404 modified "2023-10-12" @default.
• W2034625404 title "Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma" @default.
• W2034625404 cites W1749022239 @default.
• W2034625404 cites W1964988193 @default.
• W2034625404 cites W1967994046 @default.
• W2034625404 cites W1970124798 @default.
• W2034625404 cites W1972721367 @default.
• W2034625404 cites W1982060996 @default.
• W2034625404 cites W1984996099 @default.
• W2034625404 cites W1985147506 @default.
• W2034625404 cites W1993051112 @default.
• W2034625404 cites W1996971717 @default.
• W2034625404 cites W2018803923 @default.
• W2034625404 cites W2040717595 @default.
• W2034625404 cites W2041881143 @default.
• W2034625404 cites W2042774683 @default.
• W2034625404 cites W2049689068 @default.
• W2034625404 cites W2058680827 @default.
• W2034625404 cites W2075589412 @default.
• W2034625404 cites W2078002304 @default.
• W2034625404 cites W2082742146 @default.
• W2034625404 cites W2085925464 @default.
• W2034625404 cites W2089837140 @default.
• W2034625404 cites W2119810076 @default.
• W2034625404 cites W2123914905 @default.
• W2034625404 cites W2125559109 @default.
• W2034625404 cites W2129547764 @default.
• W2034625404 cites W2133157945 @default.
• W2034625404 cites W2143813821 @default.
• W2034625404 cites W2162559503 @default.
• W2034625404 cites W2210821863 @default.
• W2034625404 cites W2318508214 @default.
• W2034625404 cites W2412719933 @default.
• W2034625404 cites W2768600953 @default.
• W2034625404 cites W329302102 @default.
• W2034625404 cites W4233176852 @default.
• W2034625404 cites W99378550 @default.
• W2034625404 doi "https://doi.org/10.1002/cncr.21737" @default.
• W2034625404 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16475152" @default.
• W2034625404 hasPublicationYear "2006" @default.
• W2034625404 type Work @default.
• W2034625404 sameAs 2034625404 @default.
• W2034625404 citedByCount "22" @default.
• W2034625404 countsByYear W20346254042012 @default.
• W2034625404 countsByYear W20346254042014 @default.
• W2034625404 countsByYear W20346254042019 @default.
• W2034625404 countsByYear W20346254042023 @default.
• W2034625404 crossrefType "journal-article" @default.
• W2034625404 hasAuthorship W2034625404A5014373184 @default.
• W2034625404 hasAuthorship W2034625404A5017558949 @default.
• W2034625404 hasAuthorship W2034625404A5021341031 @default.
• W2034625404 hasConcept C126322002 @default.
• W2034625404 hasConcept C141071460 @default.
• W2034625404 hasConcept C2776364478 @default.
• W2034625404 hasConcept C2776694085 @default.
• W2034625404 hasConcept C2777472916 @default.
• W2034625404 hasConcept C2779609412 @default.
• W2034625404 hasConcept C31760486 @default.
• W2034625404 hasConcept C71924100 @default.
• W2034625404 hasConcept C90924648 @default.
• W2034625404 hasConceptScore W2034625404C126322002 @default.
• W2034625404 hasConceptScore W2034625404C141071460 @default.
• W2034625404 hasConceptScore W2034625404C2776364478 @default.
• W2034625404 hasConceptScore W2034625404C2776694085 @default.
• W2034625404 hasConceptScore W2034625404C2777472916 @default.
• W2034625404 hasConceptScore W2034625404C2779609412 @default.
• W2034625404 hasConceptScore W2034625404C31760486 @default.
• W2034625404 hasConceptScore W2034625404C71924100 @default.
• W2034625404 hasConceptScore W2034625404C90924648 @default.
• W2034625404 hasIssue "7" @default.
• W2034625404 hasLocation W20346254041 @default.
• W2034625404 hasLocation W20346254042 @default.
• W2034625404 hasOpenAccess W2034625404 @default.
• W2034625404 hasPrimaryLocation W20346254041 @default.
• W2034625404 hasRelatedWork W2006617623 @default.
• W2034625404 hasRelatedWork W2013462262 @default.
• W2034625404 hasRelatedWork W2045414143 @default.
• W2034625404 hasRelatedWork W2054498776 @default.
• W2034625404 hasRelatedWork W2085895424 @default.
• W2034625404 hasRelatedWork W2111120023 @default.
• W2034625404 hasRelatedWork W2140023433 @default.
• W2034625404 hasRelatedWork W2331412604 @default.
• W2034625404 hasRelatedWork W2387867721 @default.
• W2034625404 hasRelatedWork W4212987933 @default.
• W2034625404 hasVolume "106" @default.
• W2034625404 isParatext "false" @default.
• W2034625404 isRetracted "false" @default.
• W2034625404 magId "2034625404" @default.
• W2034625404 workType "article" @default.